Newcourt Acquisition Corp (NCAC) to Combine with Psyence Biomed

Newcourt Acquisition Corp (NCAC) to Combine with Psyence Biomed

Newcourt (NASDAQ:NCAC) has entered into a definitive agreement to combine with psychedelic medicine company Psyence (CSE:PSYG). The Canada-listed company is developing psychedelic drug candidates to potentially treat patients in palliative care and those with severe psychological conditions. The combined company is expected to continue to trade on both the Nasdaq and the Canadian Securities Exchange
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.